The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved i...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2016-10, Vol.57 (Suppl 3), p.79S-89S |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89S |
|---|---|
| container_issue | Suppl 3 |
| container_start_page | 79S |
| container_title | Journal of Nuclear Medicine |
| container_volume | 57 |
| creator | Afshar-Oromieh, Ali Babich, John W Kratochwil, Clemens Giesel, Frederik L Eisenhut, Michael Kopka, Klaus Haberkorn, Uwe |
| description | The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors
I-MIP-1972 and
I-MIP-1095. A clinical breakthrough followed in 2011 with
Ga-PSMA-11 for PET imaging and
I-MIP-1095 for endoradiotherapy of metastatic prostate cancer. Since then, PET/CT with
Ga-PSMA-11 has rapidly spread worldwide, and endoradiotherapy with PSMA ligands has been conducted at increasing numbers of centers.
Ga-PSMA-11 is currently the subject of multicenter studies in different countries. Since 2013,
I-related PSMA therapy has been replaced by
Lu-labeled ligands, such as PSMA-617, which is also the subject of multicenter studies. Alternative PSMA ligands for both imaging and therapy are available. Among them is
Tc-MIP-1404, which has recently entered a phase 3 clinical trial. This article focuses on the highlights of the development and clinical application of PSMA ligands. |
| doi_str_mv | 10.2967/jnumed.115.170720 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835349663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835349663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-bde158895f97bf2799073a4c3ce9d23b0ce30b63a9ef82f9b4228cbcbd2913733</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRS0EoqXwAWyQl2xS_Ihfy6qUhxQEgrK2bMcuqdqk2Mmif09K2tVIM-dejQ4AtxhNieLiYV13W19OMWZTLJAg6AyMMaMsY5yLczBGmOOMMcRG4CqlNUKISykvwYgIrnIs5Bgslj8eflbJwybAj6-3GSyqlanLBEMT4WNlVnWTqgT7FezRaHb7fzI2qTWth3NTOx-vwUUwm-RvjnMCvp8Wy_lLVrw_v85nReZyjNrMlh4zKRULSthAhFJIUJM76rwqCbXIeYosp0b5IElQNidEOutsSRSmgtIJuB96d7H57Xxq9bZKzm82pvZNlzSWlNFccX5A8YC6_tUUfdC7WG1N3GuM9MGeHuzp3p4e7PWZu2N9Zw-nU-Kki_4B7Etq3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835349663</pqid></control><display><type>article</type><title>The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Afshar-Oromieh, Ali ; Babich, John W ; Kratochwil, Clemens ; Giesel, Frederik L ; Eisenhut, Michael ; Kopka, Klaus ; Haberkorn, Uwe</creator><creatorcontrib>Afshar-Oromieh, Ali ; Babich, John W ; Kratochwil, Clemens ; Giesel, Frederik L ; Eisenhut, Michael ; Kopka, Klaus ; Haberkorn, Uwe</creatorcontrib><description>The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors
I-MIP-1972 and
I-MIP-1095. A clinical breakthrough followed in 2011 with
Ga-PSMA-11 for PET imaging and
I-MIP-1095 for endoradiotherapy of metastatic prostate cancer. Since then, PET/CT with
Ga-PSMA-11 has rapidly spread worldwide, and endoradiotherapy with PSMA ligands has been conducted at increasing numbers of centers.
Ga-PSMA-11 is currently the subject of multicenter studies in different countries. Since 2013,
I-related PSMA therapy has been replaced by
Lu-labeled ligands, such as PSMA-617, which is also the subject of multicenter studies. Alternative PSMA ligands for both imaging and therapy are available. Among them is
Tc-MIP-1404, which has recently entered a phase 3 clinical trial. This article focuses on the highlights of the development and clinical application of PSMA ligands.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.115.170720</identifier><identifier>PMID: 27694178</identifier><language>eng</language><publisher>United States</publisher><subject>Antigens, Surface - metabolism ; Dipeptides - pharmacokinetics ; Dipeptides - therapeutic use ; Evidence-Based Medicine ; Glutamate Carboxypeptidase II - antagonists & inhibitors ; Glutamate Carboxypeptidase II - metabolism ; Heterocyclic Compounds, 1-Ring - pharmacokinetics ; Heterocyclic Compounds, 1-Ring - therapeutic use ; Humans ; Image Enhancement ; Male ; Molecular Diagnostic Techniques ; Molecular Targeted Therapy ; Organotechnetium Compounds - pharmacokinetics ; Organotechnetium Compounds - therapeutic use ; Positron-Emission Tomography ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - radiotherapy ; Radiopharmaceuticals</subject><ispartof>Journal of Nuclear Medicine, 2016-10, Vol.57 (Suppl 3), p.79S-89S</ispartof><rights>2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-bde158895f97bf2799073a4c3ce9d23b0ce30b63a9ef82f9b4228cbcbd2913733</citedby><cites>FETCH-LOGICAL-c410t-bde158895f97bf2799073a4c3ce9d23b0ce30b63a9ef82f9b4228cbcbd2913733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27694178$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Afshar-Oromieh, Ali</creatorcontrib><creatorcontrib>Babich, John W</creatorcontrib><creatorcontrib>Kratochwil, Clemens</creatorcontrib><creatorcontrib>Giesel, Frederik L</creatorcontrib><creatorcontrib>Eisenhut, Michael</creatorcontrib><creatorcontrib>Kopka, Klaus</creatorcontrib><creatorcontrib>Haberkorn, Uwe</creatorcontrib><title>The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors
I-MIP-1972 and
I-MIP-1095. A clinical breakthrough followed in 2011 with
Ga-PSMA-11 for PET imaging and
I-MIP-1095 for endoradiotherapy of metastatic prostate cancer. Since then, PET/CT with
Ga-PSMA-11 has rapidly spread worldwide, and endoradiotherapy with PSMA ligands has been conducted at increasing numbers of centers.
Ga-PSMA-11 is currently the subject of multicenter studies in different countries. Since 2013,
I-related PSMA therapy has been replaced by
Lu-labeled ligands, such as PSMA-617, which is also the subject of multicenter studies. Alternative PSMA ligands for both imaging and therapy are available. Among them is
Tc-MIP-1404, which has recently entered a phase 3 clinical trial. This article focuses on the highlights of the development and clinical application of PSMA ligands.</description><subject>Antigens, Surface - metabolism</subject><subject>Dipeptides - pharmacokinetics</subject><subject>Dipeptides - therapeutic use</subject><subject>Evidence-Based Medicine</subject><subject>Glutamate Carboxypeptidase II - antagonists & inhibitors</subject><subject>Glutamate Carboxypeptidase II - metabolism</subject><subject>Heterocyclic Compounds, 1-Ring - pharmacokinetics</subject><subject>Heterocyclic Compounds, 1-Ring - therapeutic use</subject><subject>Humans</subject><subject>Image Enhancement</subject><subject>Male</subject><subject>Molecular Diagnostic Techniques</subject><subject>Molecular Targeted Therapy</subject><subject>Organotechnetium Compounds - pharmacokinetics</subject><subject>Organotechnetium Compounds - therapeutic use</subject><subject>Positron-Emission Tomography</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiopharmaceuticals</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAQRS0EoqXwAWyQl2xS_Ihfy6qUhxQEgrK2bMcuqdqk2Mmif09K2tVIM-dejQ4AtxhNieLiYV13W19OMWZTLJAg6AyMMaMsY5yLczBGmOOMMcRG4CqlNUKISykvwYgIrnIs5Bgslj8eflbJwybAj6-3GSyqlanLBEMT4WNlVnWTqgT7FezRaHb7fzI2qTWth3NTOx-vwUUwm-RvjnMCvp8Wy_lLVrw_v85nReZyjNrMlh4zKRULSthAhFJIUJM76rwqCbXIeYosp0b5IElQNidEOutsSRSmgtIJuB96d7H57Xxq9bZKzm82pvZNlzSWlNFccX5A8YC6_tUUfdC7WG1N3GuM9MGeHuzp3p4e7PWZu2N9Zw-nU-Kki_4B7Etq3w</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Afshar-Oromieh, Ali</creator><creator>Babich, John W</creator><creator>Kratochwil, Clemens</creator><creator>Giesel, Frederik L</creator><creator>Eisenhut, Michael</creator><creator>Kopka, Klaus</creator><creator>Haberkorn, Uwe</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201610</creationdate><title>The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer</title><author>Afshar-Oromieh, Ali ; Babich, John W ; Kratochwil, Clemens ; Giesel, Frederik L ; Eisenhut, Michael ; Kopka, Klaus ; Haberkorn, Uwe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-bde158895f97bf2799073a4c3ce9d23b0ce30b63a9ef82f9b4228cbcbd2913733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigens, Surface - metabolism</topic><topic>Dipeptides - pharmacokinetics</topic><topic>Dipeptides - therapeutic use</topic><topic>Evidence-Based Medicine</topic><topic>Glutamate Carboxypeptidase II - antagonists & inhibitors</topic><topic>Glutamate Carboxypeptidase II - metabolism</topic><topic>Heterocyclic Compounds, 1-Ring - pharmacokinetics</topic><topic>Heterocyclic Compounds, 1-Ring - therapeutic use</topic><topic>Humans</topic><topic>Image Enhancement</topic><topic>Male</topic><topic>Molecular Diagnostic Techniques</topic><topic>Molecular Targeted Therapy</topic><topic>Organotechnetium Compounds - pharmacokinetics</topic><topic>Organotechnetium Compounds - therapeutic use</topic><topic>Positron-Emission Tomography</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiopharmaceuticals</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Afshar-Oromieh, Ali</creatorcontrib><creatorcontrib>Babich, John W</creatorcontrib><creatorcontrib>Kratochwil, Clemens</creatorcontrib><creatorcontrib>Giesel, Frederik L</creatorcontrib><creatorcontrib>Eisenhut, Michael</creatorcontrib><creatorcontrib>Kopka, Klaus</creatorcontrib><creatorcontrib>Haberkorn, Uwe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Afshar-Oromieh, Ali</au><au>Babich, John W</au><au>Kratochwil, Clemens</au><au>Giesel, Frederik L</au><au>Eisenhut, Michael</au><au>Kopka, Klaus</au><au>Haberkorn, Uwe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2016-10</date><risdate>2016</risdate><volume>57</volume><issue>Suppl 3</issue><spage>79S</spage><epage>89S</epage><pages>79S-89S</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors
I-MIP-1972 and
I-MIP-1095. A clinical breakthrough followed in 2011 with
Ga-PSMA-11 for PET imaging and
I-MIP-1095 for endoradiotherapy of metastatic prostate cancer. Since then, PET/CT with
Ga-PSMA-11 has rapidly spread worldwide, and endoradiotherapy with PSMA ligands has been conducted at increasing numbers of centers.
Ga-PSMA-11 is currently the subject of multicenter studies in different countries. Since 2013,
I-related PSMA therapy has been replaced by
Lu-labeled ligands, such as PSMA-617, which is also the subject of multicenter studies. Alternative PSMA ligands for both imaging and therapy are available. Among them is
Tc-MIP-1404, which has recently entered a phase 3 clinical trial. This article focuses on the highlights of the development and clinical application of PSMA ligands.</abstract><cop>United States</cop><pmid>27694178</pmid><doi>10.2967/jnumed.115.170720</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2016-10, Vol.57 (Suppl 3), p.79S-89S |
| issn | 0161-5505 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1835349663 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antigens, Surface - metabolism Dipeptides - pharmacokinetics Dipeptides - therapeutic use Evidence-Based Medicine Glutamate Carboxypeptidase II - antagonists & inhibitors Glutamate Carboxypeptidase II - metabolism Heterocyclic Compounds, 1-Ring - pharmacokinetics Heterocyclic Compounds, 1-Ring - therapeutic use Humans Image Enhancement Male Molecular Diagnostic Techniques Molecular Targeted Therapy Organotechnetium Compounds - pharmacokinetics Organotechnetium Compounds - therapeutic use Positron-Emission Tomography Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - metabolism Prostatic Neoplasms - radiotherapy Radiopharmaceuticals |
| title | The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T13%3A55%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Rise%20of%20PSMA%20Ligands%20for%20Diagnosis%20and%20Therapy%20of%20Prostate%20Cancer&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Afshar-Oromieh,%20Ali&rft.date=2016-10&rft.volume=57&rft.issue=Suppl%203&rft.spage=79S&rft.epage=89S&rft.pages=79S-89S&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.115.170720&rft_dat=%3Cproquest_cross%3E1835349663%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835349663&rft_id=info:pmid/27694178&rfr_iscdi=true |